- Details
- David Wise discusses his work studying the role of DKK1 as a driver of some forms of CRPC with Charles Ryan. He describes that the role of immune checkpoint inhibitors in prostate cancer has been largely disappointing. Dr. Wise shares his previous findings that DKK1 is upregulated in a subset of metastatic CRPC with low or no expression of AR and that do not have features of neuroendocrine or smal...
|
- Details
- Susan Halabi provides an update on an externally validated prognostic model of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, which included eight important prognostic factors variables of overall survival: opioid analgesic use, ECOG performance status, albumin, disease site, LDH, hemoglobin, PSA, and alkaline phosphatase. They use...
|
- Details
- Jonathan Rosenberg, MD, discusses results presented of "Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Metastatic Urothelial Carcinoma — CALGB 90601" (Alliance). Dr. Rosenberg confirms that the addition of bevacizumab did not improve overall survival when added to gemcitabine and cisplatin chemotherapy a...
|
- Details
- Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning. Focusing on better treatment options for these patients and w...
|
- Details
- Clare, a clinical trial patient participant openly shares her experiences. She shares her thoughts on her decision to participate in a randomized clinical trial, her experiences with the consent form and the issues she considered when joining the trial. She is candid in her discussions with Brenda Martone. She gives us the opportunity to reflect on the options presented by being a part of a random...
|
- Details
- Oliver Sartor joins Charles Ryan in a discussion on a Phase 4 registry trial in men with metastatic castration-resistant prostate cancer (mCRPC). The IMPACT study analyses suggested that overall survival (OS) was longer in treated and control patients with low baseline PSA, and OS benefit was greatest for sipuleucel-T versus control in the patients with the lowest PSA (Schellhammer Urol 2013). Eli...
|
- Details
- Alicia Morgans discusses genetic counseling in GU cancers with Brittany Szymaniak. This conversation includes the challenges, the benefits, the concerns of genetic testing and how this is accomplished in clinical practice for people who have genital urinary malignancies, so prostate cancer, bladder cancer, kidney cancer. They also discuss the family syndromes for men with prostate cancer that shou...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the quality of life data from the ARAMIS trial. The data suggest that adding darolutamide (systemic therapy) to ADT compared to ADT alone improves quality of life in the patients, and these include bowel and urinary symptom benefits along with the skeletal outcomes and quality-of-life measures. The ARAMIS study suggests that androgen receptor antagonist da...
|
- Details
- Monty Pal and Petros Grivas discuss new approaches being taken in the neoadjuvant disease setting for bladder cancer. Petros highlights the urgent unmet need for novel therapies for bladder cancer that immunotherapy is trying to meet through innovative clinical trials. He references two clinical phase II trials, the PURE-01 by Dr. Necchi and colleagues, pembrolizumab in Cisplatin-fit patients, and...
|
- Details
- Monty Pal joins Petros Grivas to share highlights from his ASCO 2019 presentation on IMmotion150, a phase two clinical trial in kidney cancer looking at patient-reported outcomes, that compared monotherapy with atezolizumab, to sunitinib, to the combination of bevacizumab with atezolizumab, a unique opportunity to look at monotherapy in this setting. Biographies: Sumanta Kumar Pal, MD , Associate...
|
